There are conflicting data on the role of race and ethnicity in the use of renin–angiotensin system inhibitor, which are recommended for preventing DKD progression; some studies suggest lower use/prescription rates in African Caribbean populations, whereas others do not [16, 17]. Here, REN is linked to diabetic kidney disease.